Merck is investing €250 million in a new facility in Switzerland, bridging research and manufacturing, as it endeavours to speed up the availability of new medicines to patients.
The Merck Biotech Development Centre in Corsier-sur-Vevey will be dedicated to biotech development and manufacturing for clinical studies.
“This investment in the Merck Biotech Development Centre reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
Located near Merck’s current biotech commercial manufacturing site, the facility will consist of a building providing a total of 15,700 sqm of development space bringing together a cross-functional team of approximately 250 employees.
Equipped with the most advanced digital solutions and highest technological standards, it will offer a flexible-by-design infrastructure to readily adapt to emerging needs and technology evolution, as well as open workspaces enabling collaboration, creativity and innovation.
The construction is expected to be completed in 2021, with the facility slated to be fully operational by the end of 2022.